TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects with type 1 diabetes mellitus (T1DM) for at least 1 year, diagnostic criteria as defined by the American Diabetes Association~* Treated with insulin for T1DM for at least 1 year and with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening~* Hemoglobin A1c \<10%~Exclusion Criteria:~* Previously treated with dasiglucagon (previously referred to as ZP4207)~* Known or suspected allergy to trial product(s) or related products~* Females who are pregnant according to a positive pregnancy test, are actively attempting to get pregnant, or are lactating.~* History of hypoglycemic events associated with seizures in the last year prior to screening~* History of severe hypoglycemia in the last month prior to screening~* Active malignancy within the last 5 years~* Current bleeding disorder, including anti-coagulant treatment~* Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma (i.e. insulin secreting pancreas tumor)~* Use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this trial~* Clinically significant abnormal ECG at screening as judged by the investigator~* Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks prior to screening~* Surgery or trauma with significant blood loss within the last 2 months prior to screening~* A positive result in the alcohol and/or urine drug screen at the screening visit. Significant history of alcoholism or drug abuse as judged by the investigator or consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day for women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dasiglucagon (Type: EXPERIMENTAL): Single fixed dose (s.c.injection) of dasiglucagon
- Placebo (Type: PLACEBO_COMPARATOR): Single fixed dose (s.c.injection) of placebo
- GlucaGen® (Type: ACTIVE_COMPARATOR): Single fixed dose (s.c.injection) of GlucaGen®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Each participant must be at least 18 years of age~* Male, or a female who is not of child-bearing potential or who is non-pregnant, non-lactating, and is using a medically accepted method of contraception~* Each participant must have a current diagnosis of Bipolar I Disorder, current episode manic or mixed~* Each participant must be confirmed to be experiencing an acute manic or mixed bipolar 1 episode~* Each participant must have discontinued the use of all prohibited psychotropic medications~Exclusion Criteria:~* A participant must not have a primary Axis I disorder other than Bipolar 1 Disorder (i.e., an Axis 1 disorder other than Bipolar 1 Disorder that is primarily responsible for current symptoms and functional impairment)~* A participant must not currently (within the past 6 months) meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR™) criteria for substance abuse or dependence (excluding nicotine)~* A participant must not be at imminent risk of self-harm or harm to others, in the investigator's opinion based on clinical interview and responses provided on the Columbia Suicide Severity Rating Scale (CSSRS).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asenapine 5 mg BID (Type: EXPERIMENTAL): Participants were administered one 5 mg asenapine tablet, sublingually BID for 21 days
- Asenapine 10 mg BID (Type: EXPERIMENTAL): Participants were administered one 10 mg asenapine tablet, sublingually BID for 21 days
- Placebo BID (Type: PLACEBO_COMPARATOR): Participants were administered one asenapine-matched placebo tablet sublingually BID for 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MS, as defined by McDonald et al., criteria # 1-4 (McDonald et al., 2001)~* Between the ages of 18 and 50, inclusive.~* Baseline EDSS score between 0.0 and 5.0, inclusive.~* Have experienced at least one relapse within the 12 months prior to randomization.~* Cranial MRI scan demonstrating lesion(s) consistent with MS.~* Have given written informed consent to participate in the study.~Exclusion Criteria:~* Primary progressive, secondary progressive, or progressive relapsing MS.~* MS relapse has occurred,in the opinion of the investigator, within 50 days prior to randomization and/or the subject has not stabilized from a previous relapse.~* A clinically significant infectious illness within 30 days prior to randomization.~* History of, or abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal and/or other major disease, that in the opinion of the investigator, would preclude the administration of a recombinant humanized antibody immunomodulating agent for 116 weeks.~* History of severe allergic or anaphylactic reactions or known drug hypersensitivity.~* Unable to perform the Timed 25-foot Walk, 9HPT, and PASAT 3.~* Abnormal blood tests performed at the Screening Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Natalizumab 300 mg, IV
- Group 2 (Type: PLACEBO_COMPARATOR): Placebo IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Physically active a minimum of 120 minutes a week, as determined by questionnaire~* 18-35 years of age~* Classified as low risk, based on the modified PAR-Q questionnaire, BMI, and non-smoking status~* No history of pulmonary disease and pulmonary function classified as normal, as defined by the following measurements being 80% of predicted values: forced vital capacity (FVC), forced expired volume in one second (FEV1) and FEV1/FVC, according to the American Thoracic Society standards.~Exclusion Criteria:~* Current smoker~* Women who are pregnant or could possibly be pregnant~* BMI \> 25 kg/m2~* A 'yes' answer to any of the 14 questions on the PAR-Q pre-participation questionnaire~* History of pulmonary disease or \<80% of predicted FCV, FEV1 and/or FEV1/FVC.~* A history of renal or liver disease, due to possible interaction effect with Cetirizine~* Currently taking any prescription or over the counter medications for the treatment of allergies, or taking any of the below listed drugs known to have a moderate or higher interaction effect with Cetirizine:~isocarboxazid tranylcypromine bosutinib clobazam crizotinib daclatasvir eliglustat hyaluronidase lomitapide lurasidone ombitasvir/paritaprevir/ritonavir phenelzine ponatinib ritonavir vemurafenib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Cetirizine/Hypoxia (Type: EXPERIMENTAL): Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
- Placebo/Normoxia (Type: PLACEBO_COMPARATOR): Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
- Placebo/Hypoxia (Type: PLACEBO_COMPARATOR): Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets Diagnostic and Statistical Manual-IV Edition (DSM-IV) Criteria for ADHD.Combined Type~* Parent and Teacher Ratings \>85 percentile on inattention and/or hyperactivity/impulsivity scales~* Estimated Intelligence Quotient (IQ) \> 80 on Wechsler Abbreviated Scale of Intelligence or similar IQ test~Exclusion Criteria:~* Past or current diagnosis of Tourette syndrome or chronic tic disorder, Pervasive Developmental Disorder (PDD), Cerebral Palsy, Head Injury requiring hospitalization, psychotic disorder, hypertension, glaucoma, cardiovascular disease, severe narrowing of the gastrointestinal tract, or epilepsy~* Current diagnosis of bipolar disorder, obsessive-compulsive disorder serious enough to warrant separate treatment, suicidal or homicidal behavior or ideation~* Use within 14-days of a monoamine oxidase inhibitor~* History of side effects on any methylphenidate preparation that required stopping the medication~* Inability to swallow a capsule or tablet~* Chronic treatment with coumarin, clonidine, or tricyclic antidepressants

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (sugar pill);Subjects will be equally randomized and will receive one week of treatment with placebo and compared to subjects who were randomized to receive one week of OROS-methylphenidate.
- OROS-methylphenidate (Type: ACTIVE_COMPARATOR): Subjects will be equally randomized and will receive one week of treatment with the optimal dose of OROS methylphenidate compared with subjects randomized to receive one week of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Infants who meet all of the following criteria are eligible for the study:~* Mother known to be HIV-1-infected prior to labor or identified at the time of labor or \<48 hours postpartum. HIV-1 infection for the purposes of enrollment into this study is defined as: (a) Single positive HIV-1 rapid test in mother or her infant; or (b) Historical documentation of a positive HIV-1 diagnostic test confirmed by repeat diagnostic testing for HIV-1 according to country guidelines in mother (written documentation of test results must be present in the medical record).~* Maternal written informed consent for study participation.~* Mother has not received any antiretroviral therapy during the current pregnancy prior to the onset of labor and delivery; women may have received intravenous or oral ZDV during labor. Women may have received any antiretroviral therapy in previous pregnancies for prevention of vertical HIV-1 transmission.~* Infant is \<48 hours old. Infant may have received up to 48 hours of ZDV as standard care before study enrollment.~Exclusion Criteria:~Infants who meet any of the following criteria will be excluded from the study:~* Extreme prematurity (\< 32 weeks of gestation).~* Birth weight \<1500 grams.~* Presence of life-threatening conditions.~* Inability to take oral medication throughout the first 48 hours of life (must be able to receive oral medication by age 48 hours).~* Maternal inability to provide informed consent because of a lack of a conscious state, psychiatric conditions, or language barriers.~* Mother received any antiretroviral therapy during labor and delivery other than intravenous or oral ZDV.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Days
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Standard of care ( Zidovudine only)
- B (Type: EXPERIMENTAL): Standard of care (Zidovudine) plus Nevirapine
- C (Type: EXPERIMENTAL): Standard of Care (Zidovudine) plus 2 weeks of Epivir and Nelfinavir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zilver PTX Drug-Eluting Peripheral Stent Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* One de novo or restenosed artherosclerotic lesion with \> 50% diameter stenosis~* Reference vessel diameter of 4 - 9 mm~* Rutherford category ≥ 2~* Resting ankle brachial index \< 0.9~Exclusion Criteria:~* Prior stent in the study vessel~* Significant stenosis (\> 50%) or occlusion of inflow tract not successfully treated before the study procedure~* Lacks at least one patent runoff vessel~* Lesions requiring atherectomy, cutting balloons, cryoplasty balloons, or any other advanced device to facilitate stent delivery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Longer Stents (Type: EXPERIMENTAL): None
- Shorter Stents (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First-Line Treatment for HIV-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infection by HIV-2 only;~* Age \> ou = 18 years;~* Naïve for antiretroviral therapy (including antiretroviral treatment in the context of PMTCT except taking a dose of Nevirapine for PMTCT)~* CD4 \>200 cells/mm3~* Resident of the city where the study is held or of city suburbs to facilitate participation~* Signed informed consent document~Exclusion Criteria:~* Current participation in any other clinical trial~* Presence of opportunistic non-stabilized infections, of any serious or progressive disease, or of any clinical signs consistent with severe disease whose diagnosis is not yet confirmed, such as fever, weight loss, diarrhea or cough not yet explained (non-exhaustive list).~* All pathology that leads in daily life to prefer one or the other of the three therapeutic regimens for medical reasons or to change the dosages specified in the test. This includes (but not limited to):~* Hemoglobin ≤ 8 g / dL~* Neutrophil count \<500 cells/mm3~* Renal impairment with creatinine clearance \<50mL/mn~* Blood platelet \<50 000 cells/mm3~* Decompensated heart failure~* Hepatic failure Severe (TP\<50% or cytolysis severe (ALAT\> 3x ULN)~* Active TB during treatment with rifampicin~* Taking drugs that interact with the drugs of the clinical trial (as specified in the SPC)~* Pregnancy, breastfeeding or planning to become pregnant during study follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A : TDF + FTC (or 3TC) + ZDV (Type: EXPERIMENTAL): Tenofovir + Emtricitabine or Lamivudine + Zidovudine
- TDF+FTC (or 3TC) +LPV/r (Type: EXPERIMENTAL): Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
- Arm C : TDF +FTC (or 3TC) + RAL (Type: EXPERIMENTAL): Tenofovir + Emtricitabine or Lamivudine + Raltegravir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Application of Tachosil During Lymphadenectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cervical cancer (FIGO IA1, IA2, IB1, IB2)~* endometrial cancer (FIGO IA, IB, II)~* age between 18 and 70 years~* signed a written informed consent~Exclusion Criteria:~* lymph edema~* disease of the lymphatic system~* a known disease of the immune system

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TACHOSIL GROUP (Type: ACTIVE_COMPARATOR): Surgical procedures were performed by four doctors with extensive experience in oncological gynecology. A TachoSil® absorbable patch of 4.8x4.8 cm was attached, once, intraoperatively to one side of the obturator fossa (study group). Specific drainage of the retroperitoneum was performed.
- GROUP WITHOUT TACHOSIL (Type: NO_INTERVENTION): The same patient constituted also control group, because no TachoSil® absorbable patche was used on the second side of lymphadenectomy. Specific drainage of the retroperitoneum was performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1~Exclusion Criteria:~* Patients who have an ongoing serious adverse event from CHEST 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily signed informed consent for participation in this clinical study; 18 to 45 years old inclusive, male and female;~* Diagnosed uncomplicated acute infectious and inflammatory diseases of the pharynx, accompanied by a sore throat;~* Onset of first symptoms of the uncomplicated acute infectious and inflammatory diseases of the pharynx (pharyngitis and/or tonsillitis) less than 48 hours prior to inclusion into the study;~* Baseline TSS score (Tonsillopharyngitis Severity Score) ≥ 5 (total score);~Exclusion Criteria:~* Use of analgesics within \<12 hours prior to the study start or/and inability to cancel them during the study;~* Use of antibiotics within \<48 hours prior to the study start or/and inability to cancel them during the study;~* Use of local therapy (sprays, rinses, lozenges) to pharynx within \<12 hours before study start or/and inability to cancel them, besides study medications.~* Use systemic or inhaled corticosteroids within ≤1 months prior to the study start and planned therapy of them during the study (besides skin means).~* Presence of symptoms of primary bacterial pharyngitis or secondary bacterial infection (including fever over 37,5 ° C, the presence of purulent raids in the throat, severe intoxication, leukocytosis, neutrophilia, shift leukocyte left (increasing the percentage of neutrophils sticks appearance younger forms of neutrophils), increased ESR 30 mm/hr);

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment.
- Arm B (Type: ACTIVE_COMPARATOR): ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:The patient~* has a diagnosis of biopsy-verified cancer of the pharynx, larynx or oral cavity~* is referred to curative intended radiotherapy~* understands the given information and has given informed consent and~* age above 18 years.~Exclusion Criteria:~Pregnancy, lactation/breast feeding, age above 85 years, obesity (bodyweight above 140 kg), small cancers of the larynx (1A,1B), allergy to 68Ga-NOTA-AE105, metastasis on FDG-PET/CT, other previously known cancers, claustrophobia.~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 68Ga-NOTA-AE105 (Type: EXPERIMENTAL): All participants have an uPAR-PET/CT scan performed before initiation of the routine radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete